SCHEMBL25320336

SCHEMBL25320336

N#Cc1ccncc1OCc1cnccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.39
SYK P43405 3/20 0.38
FFAR1 O14842 1/20 0.38
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
XDH P47989 1/20 0.37
CYP19A1 P11511 1/20 0.37
HTT P42858 1/20 0.37
NOTUM Q6P988 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
PGGT1B P53609 1/20 0.35
SGMS2 Q8NHU3 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25321091 0.84 CYP19A1 (0.39) ALDH1A1SMN1; SMN2CYP19A1HTTNOTUM
SCHEMBL29529775 0.83 FFAR1 (0.44) IDH1FFAR1ALDH1A1SMN1; SMN2XDH
SCHEMBL25321453 0.83 FFAR1 (0.44) IDH1FFAR1ALDH1A1SMN1; SMN2XDH
SCHEMBL25320659 0.82 ALDH1A1 (0.38) FFAR1ALDH1A1SMN1; SMN2XDHCYP19A1
SCHEMBL29530120 0.82 SLC22A12 (0.39) FFAR1XDHNOTUMSGMS2SLC22A12
SCHEMBL25319656 0.82 SLC22A12 (0.39) FFAR1XDHNOTUMSGMS2SLC22A12
SCHEMBL29530250 0.82 ALDH1A1 (0.38) FFAR1ALDH1A1SMN1; SMN2XDHCYP19A1
SCHEMBL4544596 0.81 FNTA (0.53) XDHCYP19A1FNTAFNTBPGGT1B
SCHEMBL29529734 0.81 FNTA (0.53) XDHCYP19A1FNTAFNTBPGGT1B
SCHEMBL4766847 0.80 FFAR1 (0.45) SYKFFAR1ALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2023-11-16 US disclosed
CN-116997549-A Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer 蝎子疗法股份有限公司 2023-11-03 CN disclosed
EP-4217070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Scorpion Therapeutics, Inc. (US) 2023-08-02 EP disclosed
WO-2022066734-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER SCORPION THERAPEUTICS, INC. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364070-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ERBB2, EGFR, ERBB3 IDH1 326/4885SYK 587/4885FFAR1 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.